- Home
- ACCS vs CELU Comparison
ACCS vs CELU Comparison
Compare ACCS & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACCS | CELU |
|---|---|---|
| Founded | 1988 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Publishing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9M | 17.3M |
| IPO Year | 2014 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ACCS | CELU |
|---|---|---|
| Price | $5.21 | $1.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $14.00 | $6.00 |
| AVG Volume (30 Days) | 28.7K | ★ 10.8M |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 139.36 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $22,619,000.00 | ★ $26,550,000.00 |
| Revenue This Year | $7.40 | N/A |
| Revenue Next Year | $8.75 | $76.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.74 | $0.56 |
| 52 Week High | $11.35 | $2.55 |
Technical Indicators
Market Signals| Indicator | ACCS | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 40.98 | 64.82 |
| Support Level | $4.74 | $1.13 |
| Resistance Level | $5.83 | $2.55 |
| Average True Range (ATR) | 0.31 | 0.35 |
| MACD | 0.06 | 0.07 |
| Stochastic Oscillator | 36.73 | 54.29 |
Price Performance
Historical ComparisonAbout ACCS ACCESS Newswire Inc.
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.
About CELU Celularity Inc.
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.